To present advancements in mass spectrometry techniques for lipid analysis, peptide sequencing, and vaccine development.
Approach:
Targeted nano-DESI tandem MSI: Used to separate low-abundance plasmalogens from more abundant lipids in mouse brain tissue.
N-terminal chemical tagging for peptide sequencing: Implemented a coumarin-based tag to enhance de novo sequencing of short peptides.
Fentanyl vaccine development: Developed a vaccine using a chemically distinct scaffold to generate broadly cross-reactive antibodies.
Portable gas profiling: Combined miniRUEDI and GC-ECD for extended gas analysis capabilities.
Key Findings:
The nano-DESI MSI workflow resolved 38 plasmalogen species and revealed distinct distributions in mouse brain tissue.
The Me-Cou tag improved sequencing accuracy for short peptides, correctly identifying all 132 standards without misidentification.
The fentanyl vaccine generated antibodies that recognized a broad range of fentanyl-class compounds while preserving ventilation in challenged mice.
Interpretation:
Limitations:
The fentanyl vaccine remains in preclinical stages and broad analogue recognition was primarily established through binding assays.
Conclusion:
The article highlights significant progress in mass spectrometry applications across various fields, including lipidomics, peptide analysis, and immunization strategies.
